Effect of pneumococcal conjugate vaccines and SARS-CoV-2 on antimicrobial resistance and the emergence of Streptococcus pneumoniae serotypes with reduced susceptibility in Spain, 2004–20: a national surveillance study
Julio Sempere(Instituto de Salud Carlos III), José Yuste(Instituto de Salud Carlos III), Mercedes Gimeno(Meiji Pharma Spain), Covadonga Pérez-García(Instituto de Salud Carlos III), Mirian Domenech(Centro de Investigación Biomédica en Red de Enfermedades Respiratorias), Mirella Llamosí(Instituto de Salud Carlos III), Beatriz López Ruiz(Instituto de Salud Carlos III), Fernando González‐Camacho(Instituto de Salud Carlos III), Pilar Coronel(Meiji Pharma Spain), Darío Lago(Instituto de Salud Carlos III)
Cited by 69
Related Papers
Biofilm Formation Avoids Complement Immunity and Phagocytosis of Streptococcus pneumoniae
|Infection and Immunity|2013|162
Trends in invasive bacterial diseases during the first 2 years of the COVID-19 pandemic: analyses of prospective surveillance data from 30 countries and territories in the IRIS Consortium
|The Lancet Digital Health|2023|157
<i>Streptococcus pneumoniae</i> Resistance to Complement-Mediated Immunity Is Dependent on the Capsular Serotype
|Infection and Immunity|2009|117
Nationwide Trends of Invasive Pneumococcal Disease in Spain From 2009 Through 2019 in Children and Adults During the Pneumococcal Conjugate Vaccine Era
|Clinical Infectious Diseases|2020|113